Latest News

Grain and energy shipments drove $4.8 billion revenue with $100 million in productivity savings.

Net income jumped 21% as adjusted EBITDA reached record levels.

Higher-acuity shift drives guidance hikes across revenue and cash flow.

Non-bank businesses tripled contribution as quarterly net income surged 66%.

Net income surged 15.4% despite margin compression and flat loan balances.

Brookfield Infrastructure Partners is yielding a generous 4.4% as it benefits from strong growth and demand for its infrastructure assets.

These Canadian stocks distribute dividends on a monthly basis and have reliable payouts, making them ideal investments for steady cash.

Investors eagerly sold out of software titles.

This dividend stock with a current yield of 4.4% is defensive and has major growth potential, making it the perfect stock to buy on the dip.

The average Canadian TFSA balance at age 50 may be lower than expected. Here’s how investors can boost their savings.

It posted an impressive quarterly earnings report.

Starting early and adding funds consistently is a recipe for success.

These two Canadian monthly dividend stocks could help turn a $30,000 TFSA into a steady stream of tax-free income while offering room for long-term growth.

Two TSX stocks could turn a record-setting market rally into profits from trading activity and jet deliveries.

Food safety concerns negatively affected sentiment on the company.

The popular altcoin could become an AI story.

Could Moderna be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing insights that could shape your investment strategy.

The specialty financial services company posted its first quarterly earnings report of fiscal 2027.

Here's how a $25,000 TFSA portfolio can become $942 per year of steadily growing tax-free passive income.

The market and the covering analysts are more than $130 apart on this stock.

The company's financial results look much better than its stock performance this year suggests at first.

The idea of combining the two companies is no longer a fan theory. It came up on an earnings call, and the CEO didn't say no.

An analyst initiated coverage of the biotech with a buy recommendation.

Today, July 24, 2026, shares fell almost 8% as strong premarket momentum evaporated as investors refocused on increasing capex plans.

Despite ongoing concerns about inflation, high living costs and economic uncertainty, many Americans are feeling better about their finances than they did a year ago, according to Northwestern Mutual’s 2026 Planning